A randomised controlled trial on hypolipidemic effects of Nigella Sativa seeds powder in menopausal women

  • Ramlah Mohamad Ibrahim1,

    Affiliated with

    • Nurul Syima Hamdan1,

      Affiliated with

      • Rozi Mahmud2,

        Affiliated with

        • Mustapha Umar Imam3,

          Affiliated with

          • Suraini Mohd Saini2,

            Affiliated with

            • Saiful Nizam Abd Rashid2,

              Affiliated with

              • Siti Aisyah Abd Ghafar3,

                Affiliated with

                • Latiffah Ab Latiff4 and

                  Affiliated with

                  • Maznah Ismail1, 3Email author

                    Affiliated with

                    Journal of Translational Medicine201412:82

                    DOI: 10.1186/1479-5876-12-82

                    Received: 26 November 2013

                    Accepted: 4 March 2014

                    Published: 31 March 2014



                    The risk of cardiovascular diseases (CVD) is increased tremendously among menopausal women, and there is an increasing demand for alternative therapies for managing factors like dyslipidemia that contribute to CVD development.


                    In this study, Nigella sativa was evaluated for its hypolipidemic effects among menopausal women. In a randomised trial, hyperlipidemic menopausal women were assigned to treatment (n = 19) or placebo groups (n = 18), and given N. sativa or placebo for two months after their informed consents were sought. At baseline, blood samples were taken and at one month intervals thereafter until one month after the end of the study.


                    The results showed that N. sativa significantly improved lipid profiles of menopausal women (decreased total cholesterol, low density lipoprotein cholesterol and triglyceride, and increased high density lipoprotein cholesterol) more than the placebo treatment over 2 months of intervention. One month after cessation of treatment, the lipid profiles in the N. sativa-treated group tended to change towards the pretreatment levels.


                    N. sativa is thought to have multiple mechanisms of action and is cost-effective. Therefore, it could be used by menopausal women to remedy hypercholesterolemia, with likely more benefits than with single pharmacological agents that may cause side effects. The use of N. sativa as an alternative therapy for hypercholesterolemia could have profound impact on the management of CVD among menopausal women especially in countries where it is readily available.


                    Clinical trial Complementary medicine Hyperlipidemia Menopause Nigella sativa Plant bioresources


                    The incidence of cardiovascular diseases (CVD) rises significantly in women when they attain menopause. Also, CVD continues to cause significant morbidity and mortality in those women [1, 2]. In fact, the incidence of CVD is higher in menopausal women compared to women of other age groups and men of similar ages [3]. CVD is projected to remain the single leading cause of death globally and by 2020 almost 23.6 million people are projected to die from CVD particularly heart disease and stroke (WHO Death Estimated Report, 2011) [4] with significant impacts on the lives of women. The increase in CVD risk among menopausal women is mostly due to estrogen deprivation, which directly affects CVD risk factors such as dyslipidemia, diabetes mellitus, overweight, or hypertension at the time of menopause [5]. Dyslipidemia arises as a result of abnormal blood lipid profiles including especially those of high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides (TG) [6, 7], and remains one of the most important factors responsible for increased CVD risk among menopausal women. In Malaysia, CVD was reported to account for 25% of all deaths in 2008 (NCVD ACS Registry 4th Annual Report, 2011) and dyslipidemia alone, or in combination with hypertention, or with diabetes were reported to be the main factors responsible [8]. Particularly, it is reported that an increasing number of Malaysian women are suffering from CVD, likely due to rising standards of living, increasing longevity and better health care, which ensures detection of more cases [9]. The use of pharmacological agents remains the standard treatment option for dyslipidemia, however, problems of side effects have necessitated the search for better options [10].

                    Although it is a physiological transition in a woman’s life, menopause is accompanied by problems, and hence women at this age must be managed appropriately for any health risks or problems, to ensure a fulfilling life. Nowadays, there is an increasing demand for plant bioresources in the management of chronic diseases like CVD, instead of synthetic drugs, to avoid side effects [11]. Moreover, traditional medicinal plants are often cheaper, locally available, and easily consumable (raw or as simple medicinal preparations). In line with this, Nigella sativa commonly known as black seed has been widely used in many Asian, Middle Eastern and Far Eastern countries as a spice and food preservative as well as a health remedy in traditional medicine for the treatment of numerous disorders. This plant has been a great focus of research and has several traditional uses and consequently has been studied extensively for its therapeutic properties [12]. Its medicinal benefits result from its rich and diverse chemical composition including amino acids, proteins, carbohydrates, and crude fiber, oils (fixed oil with 36-38% composed of unsaturated fatty acids), minerals, alkaloids, saponin and others [13]. Furthermore, many studies have shown good potential of hypoglycaemia, hypocholesterolemia and antioxidant effects of N. Sativa, which contribute to its cardioprotective effects [1416]. However, little information exists concerning the effects of N. sativa on lipid parameters of menopausal women. Thus, we studied the effects of N. sativa seed powder on serum cholesterol, HDL-and LDL-cholesterol and TG in menopausal women for possible hypolipidemic activity.

                    Materials and method

                    Formulation of N. sativaand placebo capsules

                    Seeds of N. sativa were imported from Iran through a local company named Sari Tani Desa SDN BHD located in Shah Alam, Malaysia. Voucher specimens of seeds were kept at the Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia and the seed was identified and authenticated by Professor Dr. Maznah Ismail, Head of the Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, Malaysia. Further, N. sativa seeds were processed into pharmaceutical grade capsules containing N. sativa powder and bottled according to Good Manufacturing Practices (GMP No.: MALLP20121468). Each capsule was prepared containing 500 mg powder of N. Sativa, and each bottle contained 60 capsules, stock for a month period to help with compliance of the respondents. While for the placebo, we used wheat germ which was bought from the same company, Sari Tani Desa Sdn. Bhd. and the entire process of wheat germ capsulation was same as N. sativa seeds, however with lesser dose of 100 mg per capsule.


                    All chemicals used in this study were of analytical grade, and procured from Fisher Scientific (Loughborough, UK) and Merck (Darmstadt, Germany). Reagents and diagnostics kits used for TC, LDL, HDL and TG were supplied by Randox Laboratories Limited (Crumlin, County Antrim, UK).

                    Study subjects and protocol

                    This clinical trial was conducted at Pusat Kesihatan Universiti (PKU), Universiti Putra Malaysia (UPM). Ethical clearance was obtained from the Faculty of Medicine and Health Sciences Medical Research Ethics Committee to conduct this study (approval number: JKEUPM/LECT_AUG [08]04), which aimed to evaluate the hypolipidemic effects of N. sativa in menopausal women. Thirty seven women (n = 37), who were menopausal for at least ≥ 12 months, within the age range of 45–60 years and who presented with moderate risk of hyperlipidemia were chosen as respondents in this study. Respondents were non-smokers, did not consume alcohol and did not have a history of any other chronic disease or drug/herb ingestion. Those with any of the features above were excluded from the study. These subjects were recruited among the university’s staff or ex-staff based on a health screening. Each qualified subject was informed about the study verbally and in writing according to Good Clinical Practice. These selected subjects were randomized into 2 groups (treatment and placebo) as follows: treatment group received capsulated N. sativa powder (n = 19), while the placebo group (n = 18) received the placebo capsules. The physical and pathological histories of these subjects were recorded, and their baseline anthropometric parameters measured (Table  1). All subjects were requested to maintain their regular lifestyles including their dietary intake and physical activity. Capsules of N. sativa powder were orally administered at a dose of 1 g after breakfast every day for a period of two months. A follow- up assessment was done after the subjects completed two months treatment. Fasting venous blood (5 ml) was drawn from the subjects at baseline and at intervals during (1 month of treatment) and after the treatment period (at the end of 2 months of treatment and one month after the end of study) for further analyses. Furthermore, at each follow up interval, blood pressure measurements were taken (Table  2).
                    Table 1

                    Biodata and baseline anthropometric measurements of respondents


                    Nigella sativa (n = 19)

                    Placebo (n = 18)

                    Age (mean years)

                    53.22 ± 2.16

                    53.71 ± 3.57

                    Body weight (kg)

                    63.07 ± 8.73

                    64.85 ± 10.69

                    BMI (kg/m 2 )

                    27.18 ± 4.34

                    27.75 ± 4.38

                    Fat percentage (%)

                    37.39 ± 8.86

                    39.48 ± 8.00

                    Duration of menopause (%)


                    1-5 years



                    6-10 years



                    Ethnicity (%)











                    Marital status (%)








                    Educational level (%)














                    Employment status (%)








                    Data presented as mean ± SD for age, body weight, BMI and fat percentage, BMI: body mass index.

                    Table 2

                    Treatment effects of Nigella sativa and placebo on fasting blood glucose (FBG) and blood pressure levels



                    1 st month

                    2 nd month

                    Follow up


                    N. sativa


                    N. sativa


                    N. sativa


                    N. sativa


                    FBG (mmol/L)

                    6.37 ± 0.61*

                    5.94 ± 0.44

                    5.69 ± 0.43*

                    5.81 ± 0.31

                    5.03 ± 0.51*

                    5.73 ± 0.75

                    5.48 ± 0.42*

                    5.70 ± 0.66

                    SBP (mmHg)

                    129.33 ± 15.44

                    138.40 ± 18.90

                    121.80 ± 17.40

                    131.27 ± 19.22

                    124.53 ± 13.31

                    140.71 ± 11.85

                    125.84 ± 15.48

                    144.71 ± 19.84

                    DBP (mmHg)

                    77.13 ± 9.16

                    83.93 ± 15.73

                    76.00 ± 12.90

                    79.53 ± 13.83

                    75.53 ± 9.56

                    89.00 ± 12.53

                    75.98 ± 10.64

                    93.00 ± 15.16

                    Values are mean ± SD. There was a downward trend in the means of the groups for both N. sativa and placebo over 2 months of intervention but no significant differences were observed.

                    *Significant between N. S vs. placebo group at p < 0.05. SBP: systolic blood pressure; DBP: diastolic blood pressure.

                    Biochemical analysis

                    Whole blood was collected in plain tubes and further centrifuged at 2500 rpm for 15 min under 25°C. Serum was collected for the analyses of TC, TG, HDL and LDL levels using commercial diagnostic kits (Randox Laboratories Limited, Crumlin, County Antrim, UK) on Selectra XL chemical analyzer (Vita Scientific, Dieren, the Netherlands). Fasting blood glucose was determined using a glucometer (Roche Diagnostics, Indianapolis, IN, USA).

                    Statistical analysis

                    All experimental values are presented as means ± standard deviation (SD). Statistical analysis was performed using SPSS windows program version 19 (SPSS Institute, Inc., Chicago, IL, USA). The One-way Analysis of Variance (ANOVA) with Bonferroni correction was used for analysis of data. Difference was considered to be significant if p < 0.05.


                    This study was an attempt at determining the effects of N. sativa seeds powder on lipid profiles in humans especially among those with an increased risk of dyslipidemia (menopausal women). The baseline characteristic of the respondents in both treatment and placebo groups are presented in Table  1. Mean age of respondents in treatment and placebo groups participated in this study were 53.22 ± 2.16 and 53.71 ± 3.57, respectively. The changes in serum TC, TG, LDL and HDL are summarized in Figures  1, 2, 3, 4 for both treatment and placebo groups.
                    Figure 1

                    Changes in serum total cholesterol (TC); menopausal women randomly assigned to Nigella sativa (N.S) or placebo groups were treated for 2 months and blood samples taken at baseline, and 1 and 2 months after the start of the intervention, and one month after cessation of intervention (FL), and used to evaluate serum TC. Results are expressed as mean ± SD. *significant between N. S vs. placebo group at p < 0.05. Different letters on bars representing different intervals for the same group indicate significant difference between the intervals for the same treatment (p < 0.05).

                    Figure 2

                    Changes in serum triglyceride (TG); menopausal women randomly assigned to Nigella sativa (N.S) or placebo groups were treated for 2 months and blood samples taken at baseline, and 1 and 2 months after the start of the intervention, and one month after cessation of intervention (FL), and used to evaluate serum TG. Results are expressed as mean ± SD. *significant between N. S vs. placebo group at p < 0.05. Different letters on bars representing different intervals for the same group indicate significant difference between the intervals for the same treatment (p < 0.05).

                    Figure 3

                    Changes in serum low density lipoprotein (LDL); menopausal women randomly assigned to Nigella sativa (N.S) or placebo groups were treated for 2 months and blood samples taken at baseline, and 1 and 2 months after the start of the intervention, and one month after cessation of intervention (FL), and used to evaluate serum LDL. Results are expressed as mean ± SD. *significant between N. S vs. placebo group at p < 0.05. Different letters on bars representing different intervals for the same group indicate significant difference between the intervals for the same treatment (p < 0.05).

                    Figure 4

                    Changes in serum high density lipoprotein (HDL); menopausal women randomly assigned to Nigella sativa (N.S) or placebo groups were treated for 2 months and blood samples taken at baseline, and 1 and 2 months after the start of the intervention, and one month after cessation of intervention (FL), and used to evaluate serum HDL. Results are expressed as mean ± SD. *significant between N. S vs. placebo group at p < 0.05. Different letters on bars representing different intervals for the same group indicate significant difference between the intervals for the same treatment (p < 0.05).

                    Mean TC of the N. sativa and placebo groups at baseline, 1st and 2nd months of treatment and one month after treatment ended (follow-up) were 6.09 ± 1.04, 5.69 ± 0.99, 5.11 ± 0.91, and 5.61 ± 0.79; placebo was 6.06 ± 1.02, 5.88 ± 0.77, 5.79 ± 0.68 and 5.84 ± 0.49 mmol/L, respectively. Mean TC of the respondents in the N. sativa group improved significantly, p < 0.05, by 16.09% at two months of treatment compared to baseline and significantly greater, p < 0.05, than that in placebo group.

                    Mean TG values of the N. sativa and placebo groups at baseline, 1st and 2nd months of treatment and follow-up were 1.76 ± 0.35, 1.54 ± 0.31, 1.37 ± 0.24, and 1.29 ± 0.35; 1.72 ± 0.53, 1.68 ± 0.46, 1.56 ± 0.24 and 1.47 ± 0.51 mmol/L, respectively. Similar trend of reduction in TG levels (22.16%) as TC levels was observed with two months treatment with N. sativa seeds powder which was significantly greater, p < 0.05, than the placebo group.

                    While, mean changes of LDL-C in the treatment groups at baseline, 1st and 2nd months of treatment and follow-up were 4.65 ± 0.89, 3.89 ± 0.83, 3.41 ± 0.76 and 3.78 ± 0.58; 4.59 ± 0.48 and 4.42 ± 0.55, 4.34 ± 0.61 and 4.39 ± 0.28 mmol/L, respectively. Reduction of LDL-C was 26.67% with significant changes, p < 0.05 with two months of treatment of N. sativa seeds powder in comparison to baseline. Again, the improvements in LDL-C throughout the treatment period were significantly greater, p < 0.05 in the N. sativa group compared to the placebo group.

                    Finally, HDL-C levels in both respective treatments at baseline, 1st and 2nd months of treatment and follow-up were 1.31 ± 0.22, 1.33 ± 0.30, 1.41 ± 0.25 and 1.47 ± 0.26; 1.32 ± 0.25, 1.34 ± 0.19, 1.35 ± 0.25 and 1.38 ± 0.27 mmol/L, respectively. HDL-C was found to have improved slightly in both groups, but no significant changes (p > 0.05) were observed between the two groups. Overall, improvements of lipid profile (TC, TG and LDL-C) throughout the treatment period were significantly greater, p < 0.05 in the N. sativa group compared to the placebo group except for HDL-C levels, which was similar to that produced by placebo.

                    Although the differences in blood pressures (Table  2) were not significant between the N. sativa-treated group and the control over the period of intervention, N. sativa produced better results and significant changes were observed in fasting blood glucose. The changes in these parameters also showed similar patterns to those of lipid profile; over the 2 months of intervention, the changes showed a downward trend but increased 1 month after cessation of intervention.


                    Menopause begins 12 months after a woman's final menstrual period and is associated with a dramatic drop in estrogen levels. This change in hormone levels often contributes to adverse metabolic changes that occur during the transitional pre- and post-menopausal periods, which make women prone to diseases. It has been proposed that estrogen hormone may be responsible for the protective effects seen amongst pre-menopausal women [17]. Estrogen exerts cardio-protective action by maintaining high levels of HDL and lower levels of LDL and TG. As can be recalled, loss of this protection after menopause may therefore be responsible for increased risk of developing CVD in menopausal women [18]. Moreover, cross-sectional studies have shown high TC, and LDL and TG levels are associated with menopausal status [19, 20]. Longitudinal studies also showed increased TC, LDL, or TG levels were common at the time of menopause [21, 22].

                    In this study, we determined the hypolipidemic effects of N. sativa in menopausal women as part of the increasing drive to provide better insights into the effects of plant bioresources on health, and their potential use for therapy of chronic diseases. Also, increasing numbers of women are thought to use complementary medicines for disorders associated with their menopause, and studies like these could provide evidence-based rationale for their choice of plant bioresources. Specifically, about 75% of women were reported to be using herbal and complementary medicines in their menopausal period in place of hormone replacement therapy (HRT) due to considerations on its side effects [23]. Furthermore, the baseline data from participants in the Study of Women’s Health Across the Nation (SWAN) indicated that 48.5% had used at least one complementary or alternative therapy during their menopausal years [24]. Moreover, N. sativa proved to have many beneficial health effects, particularly as hypolipidemic agent in various clinical trials [25, 26]. To our knowledge, no clinical studies have examined the effect of N. sativa seed powder on hyperlipidemic menopausal women, while only a few have assessed the effect of N. sativa in overriectomized rats [27]. With the apparent lack of data on the effect of N. sativa in menopausal women, this study was necessitated to determine the protective effects of N. sativa on hyperlipidemic menopause women. The importance of this study is underlined by the fact that the overall cause of hyperlipidemia and the mechanisms leading up to its development in menopausal women differ considerable from in premenopausal women or men in general.

                    The results of the present study showed significant decrease in hyperlipidemia among menopausal women following treatment with N. Sativa, compared to the placebo group. The results also indicated a tendency for N. sativa to improve glycemia and blood pressure better than the placebo. Our results are in keeping with those of Inayat et al. (2009), who reported that oral treatment with N. sativa powder in hypercholesterolemic patients at the dose of 1 g daily for two months was found to reduce TC, LDL and TG, and increase HDL to highly significant extents [28]. Furthermore, TC, LDL and TG were reduced significantly after 6 months of treatment with N. sativa powder (500 mg) and statin in cardiac patients visiting Ch. Pervaiz Elahi Institute of Cardiology, Multan, Pakistan compared to placebo group receiving statin only [29]. In another study of 8 weeks at the Chamran Hospital (Isfahan, Iran), it was suggested that treatment with an oral N. sativa seed extract in male patients with mild hyperlipidemia and hypertension caused a significant dose-dependent decline in the levels of TC, TG and LDL relative to baseline data [30].

                    The hypolipidemic effects of N. sativa seeds powder does not seem to be due only to one component, but rather likely due to synergistic action of its different constituents including thymoquinone (TQ), migellamine, soluble fiber (mucilage), sterols, flavanoids and high content of polyunsaturated fatty acids (PUFAs) [31]. Additionally, in a previous study, we demonstrated that TQ in combination with other bioactive compounds in a formulation called TQ-rich fraction produced better regulation of cholesterol synthesis [3234]. Multiple mechanisms of action may in fact contribute to the lipid-lowering effects of N. sativa. Earlier, we demonstrated that N. sativa was able to regulate cholesterol synthesis through regulation of HMG-CoA reductase, Apo-A1, Apo-B100 and LDL-receptor genes, an effect mediated by TQ and other N. sativa constituents [3234]. In fact, our study had demonstrated that TQ in combination with other bioactive compounds weas better at regulation of cholesterol synthesis than TQ alone, suggesting that synergy of the compounds enhances the cholesterol-lowering effects of N. sativa[33, 34]. In addition to the control of cholesterol synthesis we have demonstrated, other mechanisms of hypolipidemic action of TQ, the active components of N. sativa, have been proposed. TQ was shown to inhibit non-enzymatic lipid peroxidation in liposome and works as a scavenger of various reactive oxygen species including superoxide anion and hydroxyl radicals [32]. Antioxidants may also partly contribute to the overall functional effects of N. Sativa. Particularly, antioxidants (flavonoids) have been proposed to decrease cholesterol synthesis and suppress reactive oxygen species, nitrogen species formation and protect the antioxidant defence system [35]. Flavanoids are also thought to enhance the efficiency of liver cells to remove LDL from the blood circulation by increasing LDL receptor densities in the liver and binding to apolipoprotein B [36]. Lipid lowering effects of dietary soluble fibers [37] and sterols [38] in N. sativa could also contribute to decreased dietary cholesterol absorption, increased primary bile synthesis and its fecal losses. Besides, high content of PUFAs in N. sativa may also result in decreased serum TC [39, 40].


                    The present study showed that N. sativa caused significant decrease in TC, LDL and TG, and slight increase in HDL among menopausal women receiving N. sativa powder at a dose of 1 g daily for two months compared to placebo group. The study also demonstrated that N. sativa may improve other biochemical indices like glycemia and blood pressure in menopausal women. With an increasing demand for more alternative therapies for menopausal women due to concerns of side effects with pharmacological therapies, and considering that multiple factors play a role in the development and complication of hyperlipidemia among menopausal women, N. sativa may be used by hyperlipidemic menopausal women as a good complementary therapy. N. sativa is an easily available and cost-effective remedy to treat dyslipidemia, and its proposed multiple mechanisms of action may produce better hypolipidemic effects compared to standard pharmacological agents or other medicinal plants with a single mechanism of action. Studies like these contribute to better understanding of N. sativa effectiveness as a therapeutic agent, and could lead to its widespread use all over the world.



                    Cardiovascular diseases


                    High density lipoprotein


                    Low density lipoprotein


                    Nigella sativa


                    Total cholesterol







                    This study was financially supported by the Research University Grant Scheme, RUGS (Vote No.: 91600), Universiti Putra Malaysia. The authors would like to thank Sari Tani Desa SDN. BHD, Shah Alam for their contribution in sample capsulation. The authors also thank the administration and staff of Pusat Kesihatan Universiti (PKU) and Institute of Bioscience (IBS), Universiti Putra Malaysia and Prof Dr. Mohd Nazri Yazid for their contribution in this study.

                    Authors’ Affiliations

                    Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia
                    Department of Imaging, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia
                    Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia
                    Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia


                    1. Sharma S, Tandon VR, Mahajan A: Menopause and cardiovascular disease. J K Sci 2008, 10:1.
                    2. Rosano GM, Vitale C, Marazzi G, Volterrani M: Menopause and cardiovascular disease: the evidence. Climacteric 2007, 10:19–24. 10.1080/13697130601114917View ArticlePubMed
                    3. Saltiki K, Doukas C, Kanakakis J, Anastasiou E, Mantzou E, Alevizaki M: Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen. Maturitas 2006, 55:51–57. 10.1016/j.maturitas.2005.12.008View ArticlePubMed
                    4. World Health Organization Institute for Public Health: Global status report on noncommunicable diseases. In The third national health and morbidity survey. Geneva: World Health Organization Press; 2010.
                    5. Atsma F, Bartelink ML, Grobbee DE, Van Der Schouw YT: Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006, 13:265–279. 10.1097/01.gme.0000218683.97338.eaView ArticlePubMed
                    6. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007, 115:450–458. 10.1161/CIRCULATIONAHA.106.637793View ArticlePubMed
                    7. Welty FK: Cardiovascular disease and dyslipidemia in women. Arch Intern Med 2001, 16:514–522.View Article
                    8. Institute of Public Health: The third national health and morbidity survey (NHMS III). 1st edition. Malaysia: Ministry of Health; 2006.
                    9. Wan Ahmad WA, Sim KH: Annual report of the NCVD-PCI registry, year 2007. National Cardiovascular Disease Database: Kuala Lumpur, Malaysia; 2009.
                    10. Pöss J, Custodis F, Werner C, Weingärtner O, Böhm M, Laufs U: Cardiovascular disease and dyslipidemia: beyond LDL. Curr Pharm Des 2011, 17:861–870. 10.2174/138161211795428858View ArticlePubMed
                    11. Gurib-Fakim A: Medicinal plants; traditions of yesterday and drugs for tomorrow. Mol Asp Med 2006, 27:1–93. 10.1016/j.mam.2005.07.008View Article
                    12. Shrivastava RM, Agrawal RC, Parveen ZJ: A review on therapeutic applications of Nigella sativa . J Chem Chem Sci 2011, 1:241–248.
                    13. Khoddami A, Ghazali HM, Yassoralipour A, Ramakrishnan Y, Ganjloo A: Physicochemical characteristics of nigella seed (Nigella sativa L.) oil as affected by different extraction methods. J Am Oil Chem Soc 2011, 88:533–540. 10.1007/s11746-010-1687-6View Article
                    14. Gilani AH, Jabeen Q, Khan MA: A review of medicinal uses and pharmacological activities of Nigella sativa . Pak J Biol Sci 2004, 7:441–451.View Article
                    15. Sabzghabaee AM, Dianatkhah M, Sarrafzadegan N, Asgary S, Ghannadi A: Clinical evaluation of nigella sativa seedsfor the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial. Med Arh 2012, 66:198–200. 10.5455/medarh.2012.66.198-200View Article
                    16. Sen N, Kar Y, Tekeli Y: Antioxidant activities of black cumin ( Nigella sativa L. ) seed cultivating in different regions in Turkey. J Food Biochem 2010, 34:105–119.View Article
                    17. Bittner V: Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol 2009, 54:2374–2375. 10.1016/j.jacc.2009.10.008View ArticlePubMed
                    18. Maturana MA, Breda V, Lhullier F, Spritzer PM: Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism 2008, 57:961–965. 10.1016/j.metabol.2008.02.012View ArticlePubMed
                    19. Tandon VR, Mahajan A, Sharma S, Sharma A: Prevalence of cardiovascular risk factors in postmenopausal women: a rural study. J Midlife Health 2010, 1:26–29.PubMed CentralPubMed
                    20. Mesalić L, Tupković E, Kendić S, Balić D: Correlation between hormonal and lipid status in women in menopause. Bosn J Basic Med Sci 2008, 8:188–192.PubMed
                    21. Feng Y, Hong X, Wilker E, Li Z, Zhang W, Jin D, Liu X, Zang T, Xu X: Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases. Atherosclerosis 2008, 196:590–597. 10.1016/j.atherosclerosis.2007.06.016View ArticlePubMed CentralPubMed
                    22. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, et al.: Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007, 115:1481–1501. 10.1161/CIRCULATIONAHA.107.181546View ArticlePubMed
                    23. Tong IL: Nonpharmacological treatment of postmenopausal symptoms. The Obstetrician & Gynaecologist 2013, 15:19–25. 10.1111/j.1744-4667.2012.00143.xView Article
                    24. Bair YA, Gold EB, Greendale GA, Sternfeld B, Adler SR, Azari R, Harkey M: Ethnic differences in use of complementary and alternative medicine at midlife: Longitudinal results from SWAN participants. Am J Pub Health 2002, 92:1832–1840. 10.2105/AJPH.92.11.1832View Article
                    25. Paarakh PM: Nigella sativa Linn- a comprehensive review. Indian J Nat Prod Resour 2010, 1:409–429.
                    26. El-Tahir KEH, Al-Ajmi MF, Al-Bekairi AM: Some cardiovascular effects of the dethymoquinonated Nigella sativa volatile oil and its major components α-pinene and p-cymene in rats. Saudi Pharm J 2003, 11:104–110.
                    27. Pourghassem-Gargari B, Ebrahimzadeh-Attary V, Rafraf M, Gorbani A: Effect of dietary supplementation with Nigella sativa L. on serum lipid profile, lipid peroxidation and antioxidant defense system in hyperlipidemic rabbits. J Med Plants Res 2009, 3:815–821.
                    28. Bhatti IU, Ur Rehman F, Khan MA, Marwat SK: Effect of prophetic medicine kalonji ( Nigella sativa ) on lipid profile of human beings. An in vivo approach. World Appl Sci J 2009, 6:1053–1057.
                    29. Tasawar Z, Siraj Z, Ahmad N, Lashari MH: The effects of Nigella sativa (Kalonji) on lipid profile in patients with stable coronary artery disease in Multan, Pakistan. Pak J Nutr 2011, 10:162–167.View Article
                    30. Dehkordi FR, Kamkhah AF: Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol 2008, 4:447–452.View Article
                    31. Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH: From here to eternity-the secret of pharaohs: therapeutic potential of black cumin seeds and beyond. Cancer Ther 2008, 6:495–510.PubMed CentralPubMed
                    32. Ismail M, Al-Naqeep G, Chan KW: Nigella sativa thymoquinone rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats. Free Radic Biol Med 2010, 48:664–672. 10.1016/j.freeradbiomed.2009.12.002View ArticlePubMed
                    33. Al-Naqeep G, Ismail M: Regulation of apolipoprotien a-1 and apolipoprotien B100 genes by thymoquinone rich fraction and thymoquinone in HepG2 cells. J Food Lipids 2009, 16:245–258. 10.1111/j.1745-4522.2009.01144.xView Article
                    34. Al-Naqeep G, Ismail M: Effects of thymoquinone rich fraction and thymoquinone on plasma lipoprotein level and hepatic low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme a Reductase gene expression. J Funct Foods 2009, 1:298–303. 10.1016/j.jff.2009.06.003View Article
                    35. Arts IC, Hollman PC: Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005, 81:317–325.
                    36. El-Beshbishy HA, Singab ANB, Sinkkonen J, Pihlaja K: Hypolipidemic and antioxidant effects of Morusalba L. (Egyptian mulberry) root bark fractions supplementation in cholesterol-fed rats. Life Sciences 2006, 78:2724–2733. 10.1016/j.lfs.2005.10.010View ArticlePubMed
                    37. Talati R, Baker WL, Pabilonia MS, White CM, Coleman CI: The effects of barley-derived soluble fiber on serum lipids. Ann Fam Med 2009, 7:157–163. 10.1370/afm.917View ArticlePubMed CentralPubMed
                    38. Moruisi KG, Oosthuizen W, Opperman AM: Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analyses. J Am Coll Nutr 2006, 25:41–48. 10.1080/07315724.2006.10719513View ArticlePubMed
                    39. Ramadan MF, Morsel JT: Characterization of phospholipid composition of black cumin (Nigella sativa L.) seed oil. Nahrung 2002, 46:240–244.View ArticlePubMed
                    40. Djoussé L, Hunt SC, Arnett DK: Dietary linoleic acid is inversely associated with plasma triacylglycerol: the national heart, lung, and blood institute family heart study. Am J Clin Nutr 2003,78(6):1098–1102.PubMed


                    © Ibrahim et al.; licensee BioMed Central Ltd. 2014

                    This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.